The announcement caught many by surprise, with the prospect of shrinking todays bulky DNA sequencers into tiny devices that could decode the building blocks of life in hours (even seconds) instead of days, being widely reported in the media.

The blogosphere was abuzz with the exciting possibilities such machines open up.

Yet perhaps it shouldnt have come as such a surprise: the firms success is built on nearly a decade of basic research at Oxford Universitys Department of Chemistry.

Professor Hagan Bayley moved to Oxford in October 2003 having already done considerable research into how tiny pores in a protein might be used to detect the molecules passing through them, work he continued to develop in his Oxford lab.

In 2005, with the backing of IP Group and the help of Isis Innovation, Hagan founded Oxford Nanopore to commercialize his ideas.

"We were looking at sensing a wide range of molecules, but it was work we did at Oxford which showed, for the first time, that our nanopores could identify all four bases of DNA," Hagan explains.

"After that it made sense to shift the firms development into the area of DNA sequencing, a move which provided an impetus for many others to follow."

Conventional sequencing requires DNA samples to be amplified (which can introduce errors), cut to the right length, attached to a bead or surface and given a fluorescent tag which has to be read with expensive imaging equipment.

The pioneering approach developed by Hagan and his team was to eliminate tags and enable individual DNA bases to be snipped off a strand one by one and then fired through a nanopore. Each base disrupts an electric current passed across the nanopore by a different amount so the DNA base letter (A, C, G or T) can be read.

"We found a modified pore that could clearly distinguish between the different bases," Hagan tells me, "but the big prize was strand sequencing  being able to pull a whole strand of DNA through a pore and read out the bases one at a time from that. It was work done at Oxford that first showed that this was possible."

Despite his role as the firms founder, a board member, and long-time scientific adviser, Hagan didnt become its CEO; "my interest was always in the basic research" he says.

Instead, he continued to work with his team on the scientific challenges of understanding nanopores and what they can do, publishing papers that were useful to both the spinout and others interested in the potential of this emerging technology.

Yet the relationship remained a close one: former members of Hagans group would go on to play a significant role in the firms development as it grew from a small start-up to a company now employing 120 people.

Drawing on the basic research, Oxford Nanopore has been working hard for the last few years on creating the electronic hardware and software necessary to turn the nanopore concept into viable commercial devices. Its new MinION and GridION sequencers have already been hailed as game-changing products on the road to cheaper, faster, more flexible DNA sequencing but this could be just the start, Hagan suggests: "we could see a high-throughput chip reading signals from hundreds of thousands of nanopores simultaneously, this could be very important for large-scale sequencing."

After a decade of working in this area Hagan believes it is now time for him to move on and find new avenues of research.

He believes that most new commercial exploitation opportunities come from basic research, and instead of research councils and universities trying to plan pathways to new products and services: "the best way to do initial research is to find good motivated scientists, give them funding and time, and leave them alone."

Hagan tells me: "we need to make it simple for academics to form a company, dont make them have to take a year out from their academic work or quit their university job to get things going." The support he received from Isis Innovation and others around the University indeed made spinning out a firm relatively easy.

His message to funders and universities is that its how you treat your researchers that counts; support them and, in time, everyone will reap the rewards.

Related Stories

(PhysOrg.com) -- Oxford University spinoff company, Oxford Nonopore has announced at this years Advances in Genome Biology and Technology conference in Florida, two new machines for sequencing genes. ...

(PhysOrg.com) -- Over the past 5 years, researchers have been exploring the use of nanoscale pores as nucleic acid sequencing tools. In theory, such pores should generate a unique response characteristic of each of the four ...

Research published this week in Nature Nanotechnology shows a new method of enzyme-controlled movement of a single strand of DNA through a protein nanopore. The paper, by researchers at the University of California Santa ...

Research published this week in JACS (Journal of the American Chemical Society) shows continuous and controlled translocation of a single stranded DNA (ssDNA) polymer through a protein nanopore by a DNA polymerase enzyme. The ...

Oxford Nanopore Technologies today announced an exclusive agreement with Harvard University's Office of Technology Development for the development of graphene for DNA sequencing. Graphene is a robust, single ...

Scientists are one step closer to a revolution in DNA sequencing, following the development in a Harvard lab of a tiny device designed to read the minute electrical changes produced when DNA strands are passed ...

Recommended for you

(Phys.org)—As lithium resources continue to decline worldwide, the next generation of portable electronics will most likely be powered by something other than Li-ion batteries. One potential candidate is ...

Dislocations in oxides such as cerium dioxide, a solid electrolyte for fuel cells, turn out to have a property that is the opposite of what researchers had expected, according to a new analysis at MIT.

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy ...

A novel nucleating agent that builds on the concept of molecularly imprinted polymers (MIPs) could allow crystallographers access to proteins and other biological macromolecules that are usually reluctant ...

Researchers from institutions including Lund University have taken a step closer to producing solar fuel using artificial photosynthesis. In a new study, they have successfully tracked the electrons' rapid transit through ...

I wouldn't go so far as saying it's a hoax but on the other hand I've been in companies that tweaked statistics in their favor; the product kind-of-sort-of did as advertised but in the end was a flop.

Nanopores are still poorly understood, as is the behavior of long molecular chains inside pores. Also the 4% read error means you need a lot of reads to push the error to something useful. 30 reads at $900 each isn't competitive in the least. If they can get below 1% it becomes a game changer.

However it's awesome anyways as it becomes a portable (very expensive) Star Trek style tricorder. I can in theory squish any sample in the device and read it. 4% error does not qualify as medically relevant for personal genetics but it is even excessive if I only wish to identify something, say a bacteria pulled from a leg wound. I meet even be able to determine drug resistance.